Comparative Pharmacology
Head-to-head clinical analysis: AMICAR versus NUMBRINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMICAR versus NUMBRINO.
AMICAR vs NUMBRINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
Selective serotonin reuptake inhibitor (SSRI); increases synaptic serotonin by inhibiting SERT.
4-5 g IV loading dose over 1 hour, followed by 1 g/hour IV continuous infusion for 8 hours or until bleeding controlled; oral: 5 g PO initially, then 1-1.25 g PO every hour as needed.
2 mg/kg intravenously every 8 hours, max 150 mg per dose.
None Documented
None Documented
Terminal elimination half-life: 2 hours (range 1-3.5 hours). After high doses or renal impairment, half-life may prolong (up to 5-10 hours).
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min)
Renal: >99% of absorbed dose excreted unchanged in urine. Biliary/fecal: negligible (<1%).
Renal: 70% unchanged; hepatic metabolism: 20%; fecal: 10%
Category C
Category C
Antifibrinolytic
Antifibrinolytic